About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT06113081

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

This study is designed to describe the clinical activity and safety profile of mogamulizumab at standard dose in the treatment of CTCL patients in real world setting

Lead sponsor: Fondazione Italiana Linfomi - ETS•21 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

Fondazione Italiana Linfomi - ETS

Mogamulizumab (anti-CCR4) has been recently approved and reimbursed in Italy for the treatment of Cutaneous T-cell lymphoma (CTCL) after 1 previous systemic treatment based on the favourable results of the MAVORIC clinical trial. To date, no real-world data on significant series of patients treated routinely with mogamulizumab in clinical practice are available. As real-life data are essential to confirm the preliminary evidence displayed in phase III trials, this study aims at describing the clinical activity and safety profile of mogamulizumab at standard dose in the treatment of CTCL patients in real world settings.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Confirmed diagnosis of CTCL according to the EORTC 2017 update criteria (Trautinger et al, Eur J Cancer, 2017)
•Age ≥18 years
•Have failed at least one previous line of systemic therapy
•Have received mogamulizumab in real life setting after the approval and reimbursement of the drug from the National Health System in December 2020
•Have received first dose of mogamulizumab between 01/01/2021 and 31/01/2023
•Have received mogamulizumab at the standard approved dose (1.0 mg/kg intravenously on days 1, 8, 15 and 22 of the first cycle and on days 1 and 15 of subsequent cycles)
•Availability of complete medical records.

Related studies

RECRUITINGPhase 1

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

NCT05414500 · Cutaneous T Cell Lymphoma, Mycosis Fungoides

RECRUITINGPhase 1/2

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

NCT05589896 · Acute Leukemia, Acute Lymphoblastic Leukemia, and more

RECRUITINGPhase 2

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

NCT07356245 · T-cell Lymphoma, Graft Versus Host Disease, and more

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

NCT06588868 · Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, and more

RECRUITINGPhase 2

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

NCT06716658 · Lymphoma, T-Cell, NK-LGL Leukemia, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 24, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment100

Start dateJun 2024

Last updatedDec 24, 2025

Condition

Cutaneous T Cell Lymphoma Cutaneous T-Cell Lymphoma/Mycosis Fungoides Cutaneous T-Cell Lymphoma/Sezary Syndrome

Locations shown

Clinica di Ematologia - AOU Ospedali Riuniti delle Marche

Ancona

S.C. Ematologia e Trapianto emopoietico - A.O. S.Giuseppe Moscati

Avellino

Clinica Dermatologia - A.O.U. Policlinico Consorziale

Bari

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 24, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions